Back to top
more

Natera (NTRA)

(Delayed Data from NSDQ)

$175.01 USD

175.01
801,015

+2.85 (1.66%)

Updated Sep 16, 2025 04:00 PM ET

Pre-Market: $175.00 -0.01 (-0.01%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Surprise Coming for Natera (NTRA) This Earnings Season?

by Zacks Equity Research

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Wall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 82.9% in Natera (NTRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pediatrix Medical Group (MD) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of -24.53% and 4.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street Analysts Predict a 47% Upside in Natera (NTRA): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 47.5% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline

by Zacks Equity Research

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Illumina (ILMN)

by Kevin Cook

Leader in genomic sequencing still growing sales over 15% as lifescience labs crunch more genetic data

Zacks Equity Research

Earnings Preview: Natera (NTRA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Does Natera (NTRA) Have the Potential to Rally 76% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 75.6% upside potential for Natera (NTRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 3.33% and 8.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Natera (NTRA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -19.35% and 2.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Teladoc (TDOC) delivered earnings and revenue surprises of 88.14% and 1.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Natera (NTRA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

by Kevin Cook

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

Zacks Equity Research

Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -28.35% and 2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.

Zacks Equity Research

Should You Buy Natera (NTRA) Ahead of Earnings?

by Zacks Equity Research

Natera (NTRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts Believe Natera (NTRA) Could Rally 27%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Natera (NTRA) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

by Kevin Cook

Key M&A boosts sales & EPS, opens path to new business with Clinical Genomics Division